Autism spectrum disorder (ASD) is a heterogeneous, neurodevelopmental disorder with core symptoms including deficits in social interaction, difficulties in communication, and restricted, repetitive behaviors. Behavioral and developmental therapies are the cornerstone of ASD treatment, regardless of severity, and many patients also receive drug therapy to help manage specific symptoms or comorbidities, such as attention deficit, hyperactivity, irritability, and aggression. The only FDA-approved treatments for ASD are risperidone and aripiprazole, which are indicated for irritability associated with ASD. Other drug classes that may be used in the treatment of ASD include antidepressants, stimulants, and antiepileptics. Significant unmet need remains for pharmacological therapies to treat the core symptoms of ASD, but it is unclear if any pipeline agent can capitalize on this significant commercial opportunity.

QUESTIONS ANSWERED

  •  How large is the diagnosed prevalent ASD population in the United States and EU5 and how will it change through 2027?
  • What is the current treatment landscape for ASD patients and how will it change in the next 10 years? What clinical needs remain unfulfilled?
  •  Which emerging therapies do ASD specialists consider the most promising and which are likely to launch by 2027? What is the commercial impact of these new ASD therapies?

PRODUCT DESCRIPTION
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Autism Spectrum Disorder - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Tamara Blutstein, PhD; Alison Isherwood, MSc, MRes, PhD

Tamara Blutstein is a Senior Business Insights Analyst on the Central Nervous System, Pain, and Ophthalmology team. She is responsible for analyzing and forecasting pharmaceutical markets, primarily in Neurology indications, with specific expertise in Alzheimer’s disease, Parkinson’s disease, and ischemic stroke.

Prior to joining the company, Tamara was a postdoctoral fellow at Tufts University School of Medicine, where she studied the role of gliotransmission in the regulation of sleep and sleep homeostasis. She earned a Ph.D. in neuroscience from the University of Maryland School of Medicine where she conducted research on the role of gonadal hormones in modulating neuronal-glial communication. She holds a B.A. in neuroscience from Drew University.

Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.